Amprenavir
FDA-approved product (capsule, oral), marketed as Agenerase.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- HIV infection
- Viral disease
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Protease inhibitors
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE05
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA40.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli39.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae20.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis67.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Amprenavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir
NCT00001095
Registered record
- Registry ID
- NCT00001095
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Amprenavir; Nevirapine; Lamivudine; Stavudine; Zidovudine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 1999-10
- Enrolment
- 94
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; Amprenavir; Nevirapine; Lamivudine +2 morePhasePhase 2Registry statusCompletedSafety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir
NCT00001133
Registered record
- Registry ID
- NCT00001133
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Ritonavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 2006-08
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; RitonavirPhasePhase 1Registry statusCompletedA Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection
NCT00002183
Registered record
- Registry ID
- NCT00002183
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate; Amprenavir; Lamivudine; Zidovudine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionAbacavir sulfate; Amprenavir; Lamivudine; ZidovudinePhasePhase 1Registry statusCompletedSafety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors
NCT00002193
Registered record
- Registry ID
- NCT00002193
- Conditions
- HIV Infections
- Interventions
- Amprenavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 210
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionAmprenavirPhasePhase 3Registry statusCompletedA Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients
NCT00002195
Registered record
- Registry ID
- NCT00002195
- Conditions
- HIV Infections
- Interventions
- Amprenavir; Lamivudine; Zidovudine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 290
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionAmprenavir; Lamivudine; ZidovudinePhasePhase 3Registry statusCompletedAn Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen
NCT00002205
Registered record
- Registry ID
- NCT00002205
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate; Amprenavir
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionAbacavir sulfate; AmprenavirPhaseNot applicableRegistry statusCompletedThe Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors
NCT00002213
Registered record
- Registry ID
- NCT00002213
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate; Amprenavir; Efavirenz
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionAbacavir sulfate; Amprenavir; EfavirenzPhasePhase 2Registry statusCompletedA Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs
NCT00002217
Registered record
- Registry ID
- NCT00002217
- Conditions
- HIV Infections
- Interventions
- Lamivudine/Zidovudine; Abacavir sulfate; Amprenavir
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionLamivudine/Zidovudine; Abacavir sulfate; AmprenavirPhaseNot applicableRegistry statusCompletedA Study of a Combination of Four Drugs in Patients With Recent HIV Infection
NCT00002233
Registered record
- Registry ID
- NCT00002233
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Abacavir sulfate; Amprenavir; Lamivudine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; Abacavir sulfate; Amprenavir; LamivudinePhasePhase 2Registry statusCompletedA Study of 141W94 in Combination With Other Anti-HIV Drugs
NCT00002372
Registered record
- Registry ID
- NCT00002372
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Amprenavir; Nelfinavir mesylate; Saquinavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; Amprenavir; Nelfinavir mesylate; SaquinavirPhasePhase 1Registry statusCompletedA Study of Amprenavir in HIV-Infected Patients
NCT00002405
Registered record
- Registry ID
- NCT00002405
- Conditions
- HIV Infections
- Interventions
- Amprenavir
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionAmprenavirPhaseNot applicableRegistry statusCompletedA Study of Amprenavir in Patients With Protease Inhibitor-Related Complications
NCT00002417
Registered record
- Registry ID
- NCT00002417
- Conditions
- HIV Infections
- Interventions
- Amprenavir
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionAmprenavirPhaseNot applicableRegistry statusCompletedSafety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment
NCT00002419
Registered record
- Registry ID
- NCT00002419
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate; Amprenavir; Efavirenz; Adefovir dipivoxil
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionAbacavir sulfate; Amprenavir; Efavirenz; Adefovir dipivoxilPhasePhase 2Registry statusCompletedA Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive Patients
NCT00002426
Registered record
- Registry ID
- NCT00002426
- Conditions
- HIV Infections
- Interventions
- Adefovir dipivoxil
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 390
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionAdefovir dipivoxilPhaseNot applicableRegistry statusCompletedA Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
NCT00002440
Registered record
- Registry ID
- NCT00002440
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Ritonavir; Abacavir sulfate; Amprenavir; Nelfinavir mesylate; Saquinavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; Ritonavir; Abacavir sulfate; Amprenavir +2 morePhasePhase 2Registry statusCompleted